Parker Institute for Cancer Immunotherapy

Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial

Abstract We conducted a randomized surgical window-of-opportunity trial ( NCT04606316 ) in recurrent, resectable glioblastoma. Between 2021 and 2024, 71 patients were screened, and 63 were randomized (intention-to-treat [ITT] population), and 58 received study treatment. Patients...

Farnesyltransferase Enables Modular Assembly of Dual‐Functional Nanobody Conjugates for in Vivo Imaging of Inflammation

ABSTRACT Non‐invasive imaging of inflammation is critical for disease diagnosis, monitoring, and therapeutic evaluation. Nanobodies, due to their many unique properties, are emerging as powerful imaging agents; however, conventional non‐specific conjugation strategies often yield...